Vimtop Dosage

How old is patient?
sponsored

Dosage of Vimtop in details

sponsored

Vimtop Dosage

Applies to the following strength(s): 400 intl units/mL; 1000 intl units; 2000 intl units; 400 intl units; 5000 intl units; 50,000 intl units; 14,000 intl units; 10,000 intl units/mL; 4000 intl units; 5000 intl units/mL; 400 intl units/0.028 mL; 1000 intl units/drop; 10000 intl units; 25,000 intl units; 1000 intl units/10 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Vitamin D Insufficiency

600 to 2,000 international units, orally, once a day

Maximum dose: 4,000 international units per day

Usual Adult Dose for Vitamin D Deficiency

Initial dose:

50,000 international units, once a week, for 8 weeks

or

6,000 international units, once a day, for 8 weeks

Maintenance dose: 1,500 to 2,000 international units, once a day

Maximum dose: 10,000 international units per day

Comments:

-Target blood levels above 30 ng/mL of 25(OH)D.

Usual Adult Dose for Prevention of Falls

800 international units, orally, once a day

-1,500 to 2,000 international units, once a day, may be needed to achieve blood levels of 25(OH)D above 30 ng/mL.

Usual Geriatric Dose for Prevention of Fractures

Over 70 years: 800 to 2,000 international units, orally, once a day

Usual Pediatric Dose for Vitamin D Insufficiency

0 to 12 months: 400 international units once a day

1 to 18 years: 600 international units once a day

Maximum dose:

-Up to 6 months: 1,000 international units per day

-7 months to 1 year: 1,500 international units per day

-1 to 3 years: 2,500 international units per day

-4 to 8 years: 3,000 international units per day

-9 years and older: 4,000 international units per day

Usual Pediatric Dose for Vitamin D Deficiency

-Up to 1 year old: 2,000 international units, orally, once a day, for 6 weeks

or

50,000 international units, once a week, for 6 weeks

Maintenance dose: 400 to 1,000 international units per day

-1 to 18 years: 2,000 international units, orally, once a day for at least 6 weeks

or

50,000 international units, once a week, for at least 6 weeks

Maintenance dose: 600 to 1,000 international units per day

Maximum dose:

-Up to 1 year: 2,000 international units per day

-1 to 18 years: 4,000 international units per day

Comments:

-Target blood levels above 30 ng/mL of 25(OH)D.

Renal Dose Adjustments

Do not use in severe renal impairment

Liver Dose Adjustments

Data not available

Dose Adjustments

Pregnancy or Lactation: 600 to 2,000 international units once a day; maximum 4,000 international units per day

-1,500 to 2,000 international units, once a day, may be needed to achieve blood levels of 25(OH)D above 30 ng/mL.

Obesity, Malabsorption Syndromes, or Medications Affecting Vitamin D Absorption:

-Treatment of Deficiency: 6,000 to 10,000 international units, once a day, until blood levels of 25(OH)D are above 30 ng/mL.

-Maintenance dose: 1,500 to 2,000 international units, once a day

Patients on anticonvulsants, glucocorticoids, antifungals such as ketoconazole, or medications for acquired immune deficiency syndrome may require 2 to 3 times more vitamin D.

Provide medical supervision if upper limits are exceeded.

Dialysis

Vitamin D and its metabolites are not dialyzable.

More about Vimtop

Consumer resources

Professional resources

Related treatment guides

What other drugs will affect Vimtop?

Ask a doctor or pharmacist if it is safe for you to use Vimtop if you are also using any of the following drugs:

This list is not complete. Other drugs may interact with Vimtop, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Vimtop interactions

sponsored

Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol)

Cholestyramine

Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; as such it may impair intestinal absorption of any of vitamin D

Phenytoin/Phenobarbital

The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism. Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously

Thiazides

Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary

Digitalis

Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias

Ketoconazole

Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D. Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men. However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated

Corticosteroids

A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption

Phosphate-Binding Agents

Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration

Vitamin D

The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia

Calcium Supplements

Uncontrolled intake of additional calcium-containing preparations should be avoided

Magnesium

Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.


sponsored

References

  1. DailyMed. "ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "BIOTIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. FDA/SPL Indexing Data. "V91P54KPAM: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Vimtop are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vimtop. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved